Skip to main content
Top
Published in:

Open Access 01-02-2025 | Sheehan Syndrome

Sheehan syndrome: a current approach to a dormant disease

Authors: Zuleyha Karaca, Fahrettin Kelestimur

Published in: Pituitary | Issue 1/2025

Login to get access

Abstract

Sheehan syndrome (SS) is postpartum pituitary necrosis leading to severe hypopituitarism. Severe bleeding during delivery and postpartum period results in ischemic necrosis of the enlarged pituitary gland during pregnancy. The improved obstetrical care decreased the incidence of SS significantly, however SS should always be kept in mind in the etiologies of hypopitutarism in women which can be easily recognized by medical history of the patient. The nonspecific signs and symptoms of hypopituitarism result in significant delay in diagnosis and treatment. The diagnostic delay makes the patients to expose hypopituitarism without essential replacement therapies leading to increased morbidity and mortality of the patients. Awareness of physicians about SS is critical for the diagnosis of the disease. In this review, the epidemiology, pathophysiology, clinical manifestations and treatment of SS are discussed in the light of recent studies.
Literature
1.
go back to reference Sheehan HL (1937) Post-partum necrosis of the anterior pituitary. J Pathol Bacteriol 45:189–214CrossRef Sheehan HL (1937) Post-partum necrosis of the anterior pituitary. J Pathol Bacteriol 45:189–214CrossRef
2.
go back to reference Abs R, Bengtsson BA, Hernberg-Stâhl E, Monson JP, Tauber JP, Wilton P et al (1999) GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol (Oxf) 50:703–713PubMedCrossRef Abs R, Bengtsson BA, Hernberg-Stâhl E, Monson JP, Tauber JP, Wilton P et al (1999) GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol (Oxf) 50:703–713PubMedCrossRef
3.
go back to reference Diri H, Karaca Z, Tanriverdi F, Unluhizarci K, Kelestimur F (2016) Sheehan’s syndrome: new insights into an old disease. Endocrine 51:22–31PubMedCrossRef Diri H, Karaca Z, Tanriverdi F, Unluhizarci K, Kelestimur F (2016) Sheehan’s syndrome: new insights into an old disease. Endocrine 51:22–31PubMedCrossRef
4.
go back to reference Diri H, Tanriverdi F, Karaca Z, Senol S, Unluhizarci K, Durak AC et al (2014) Extensive investigation of 114 patients with Sheehan’s syndrome: a continuing disorder. Eur J Endocrinol 171:311–318PubMedCrossRef Diri H, Tanriverdi F, Karaca Z, Senol S, Unluhizarci K, Durak AC et al (2014) Extensive investigation of 114 patients with Sheehan’s syndrome: a continuing disorder. Eur J Endocrinol 171:311–318PubMedCrossRef
5.
go back to reference Ramiandrasoa C, Castinetti F, Raingeard I, Fenichel P, Chabre O, Brue T et al (2013) Delayed diagnosis of Sheehan’s syndrome in a developed country: a retrospective cohort study. Eur J Endocrinol 169:431–438PubMedCrossRef Ramiandrasoa C, Castinetti F, Raingeard I, Fenichel P, Chabre O, Brue T et al (2013) Delayed diagnosis of Sheehan’s syndrome in a developed country: a retrospective cohort study. Eur J Endocrinol 169:431–438PubMedCrossRef
6.
go back to reference Karaca Z, Laway BA, Dokmetas HS, Atmaca H, Kelestimur F (2016) Sheehan syndrome. Nat Rev Dis Primers 2:16092PubMedCrossRef Karaca Z, Laway BA, Dokmetas HS, Atmaca H, Kelestimur F (2016) Sheehan syndrome. Nat Rev Dis Primers 2:16092PubMedCrossRef
7.
go back to reference Regal M, Páramo C, Sierra SM, Garcia-Mayor RV (2001) Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin Endocrinol (Oxf) 55:735–740PubMedCrossRef Regal M, Páramo C, Sierra SM, Garcia-Mayor RV (2001) Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin Endocrinol (Oxf) 55:735–740PubMedCrossRef
8.
go back to reference Elumir-Mamba LAS, Andag-Silva AA, Fonte JS, Mercado-Asis LB (2010) Clinical profile and etiology of hypopituitarism at the university of santo tomas hospital. Phillippine J Intern Med 48:23–28 Elumir-Mamba LAS, Andag-Silva AA, Fonte JS, Mercado-Asis LB (2010) Clinical profile and etiology of hypopituitarism at the university of santo tomas hospital. Phillippine J Intern Med 48:23–28
9.
go back to reference Zargar AH, Singh B, Laway BA, Masoodi SR, Wani AI, Bashir MI (2005) Epidemiologic aspects of postpartum pituitary hypofunction (Sheehan’s syndrome). Fertil Steril 84:523–528PubMedCrossRef Zargar AH, Singh B, Laway BA, Masoodi SR, Wani AI, Bashir MI (2005) Epidemiologic aspects of postpartum pituitary hypofunction (Sheehan’s syndrome). Fertil Steril 84:523–528PubMedCrossRef
10.
go back to reference Kristjansdottir HL, Bodvarsdottir SP, Sigurjonsdottir HA (2011) Sheehan’s syndrome in modern times: a nationwide retrospective study in Iceland. Eur J Endocrinol 164:349–354PubMedCrossRef Kristjansdottir HL, Bodvarsdottir SP, Sigurjonsdottir HA (2011) Sheehan’s syndrome in modern times: a nationwide retrospective study in Iceland. Eur J Endocrinol 164:349–354PubMedCrossRef
11.
go back to reference Karaca Z, Tanriverdi F, Unluhizarci K, Kelestimur F (2010) Pregnancy and pituitary disorders. Eur J Endocrinol 162:453–475PubMedCrossRef Karaca Z, Tanriverdi F, Unluhizarci K, Kelestimur F (2010) Pregnancy and pituitary disorders. Eur J Endocrinol 162:453–475PubMedCrossRef
12.
go back to reference Lust K, McIntyre HD, Morton A (2001) Sheehan’s syndrome–acute presentation with hyponatraemia and headache. Aust N Z J Obstet Gynaecol 41:348–351PubMedCrossRef Lust K, McIntyre HD, Morton A (2001) Sheehan’s syndrome–acute presentation with hyponatraemia and headache. Aust N Z J Obstet Gynaecol 41:348–351PubMedCrossRef
13.
go back to reference Roberts DM (1988) Sheehan’s syndrome. Am Fam Physician 37:223–227PubMed Roberts DM (1988) Sheehan’s syndrome. Am Fam Physician 37:223–227PubMed
14.
go back to reference Laway BA, Sharma A, Choh NA, Shaheen F, Wani AI (2023) Sella turcica size in women with sheehan syndrome-a case-control study. Indian J Endocrinol Metab 27:431–435PubMedPubMedCentralCrossRef Laway BA, Sharma A, Choh NA, Shaheen F, Wani AI (2023) Sella turcica size in women with sheehan syndrome-a case-control study. Indian J Endocrinol Metab 27:431–435PubMedPubMedCentralCrossRef
15.
go back to reference Erez O, Mastrolia SA, Thachil J (2015) Disseminated intravascular coagulation in pregnancy: insights in pathophysiology, diagnosis and management. Am J Obstet Gynecol 213:452–463PubMedCrossRef Erez O, Mastrolia SA, Thachil J (2015) Disseminated intravascular coagulation in pregnancy: insights in pathophysiology, diagnosis and management. Am J Obstet Gynecol 213:452–463PubMedCrossRef
16.
go back to reference Cakir I, Tanriverdi F, Karaca Z, Kaynar L, Eser B, Unluhizarci K et al (2012) Evaluation of coagulation and fibrinolytic parameters in adult onset GH deficiency and the effects of GH replacement therapy: a placebo controlled study. Growth Horm IGF Res 22:17–21PubMedCrossRef Cakir I, Tanriverdi F, Karaca Z, Kaynar L, Eser B, Unluhizarci K et al (2012) Evaluation of coagulation and fibrinolytic parameters in adult onset GH deficiency and the effects of GH replacement therapy: a placebo controlled study. Growth Horm IGF Res 22:17–21PubMedCrossRef
17.
go back to reference Gokalp D, Tuzcu A, Bahceci M, Ayyildiz O, Yurt M, Celik Y et al (2011) Analysis of thrombophilic genetic mutations in patients with Sheehan’s syndrome: is thrombophilia responsible for the pathogenesis of Sheehan’s syndrome? Pituitary 14:168–173PubMedCrossRef Gokalp D, Tuzcu A, Bahceci M, Ayyildiz O, Yurt M, Celik Y et al (2011) Analysis of thrombophilic genetic mutations in patients with Sheehan’s syndrome: is thrombophilia responsible for the pathogenesis of Sheehan’s syndrome? Pituitary 14:168–173PubMedCrossRef
18.
go back to reference Ghosh J, Dharamdasani S, Parthan G, Shah R, Dutta P (2024) Sheehan’s syndrome in a patient with factor XI deficiency. Cureus 16:e62328PubMedPubMedCentral Ghosh J, Dharamdasani S, Parthan G, Shah R, Dutta P (2024) Sheehan’s syndrome in a patient with factor XI deficiency. Cureus 16:e62328PubMedPubMedCentral
19.
go back to reference De Bellis A, Kelestimur F, Sinisi AA, Ruocco G, Tirelli G, Battaglia M et al (2008) Anti-hypothalamus and anti-pituitary antibodies may contribute to perpetuate the hypopituitarism in patients with Sheehan’s syndrome. Eur J Endocrinol 158:147–152PubMedCrossRef De Bellis A, Kelestimur F, Sinisi AA, Ruocco G, Tirelli G, Battaglia M et al (2008) Anti-hypothalamus and anti-pituitary antibodies may contribute to perpetuate the hypopituitarism in patients with Sheehan’s syndrome. Eur J Endocrinol 158:147–152PubMedCrossRef
20.
go back to reference Goswami R, Kochupillai N, Crock PA, Jaleel A, Gupta N (2002) Pituitary autoimmunity in patients with Sheehan’s syndrome. J Clin Endocrinol Metab 87:4137–4141PubMedCrossRef Goswami R, Kochupillai N, Crock PA, Jaleel A, Gupta N (2002) Pituitary autoimmunity in patients with Sheehan’s syndrome. J Clin Endocrinol Metab 87:4137–4141PubMedCrossRef
21.
go back to reference González-González JG, Borjas-Almaguer OD, Salcido-Montenegro A, Rodríguez-Guajardo R, Elizondo-Plazas A, Montes-de-Oca-Luna R (2018) Sheehan’s syndrome revisited: underlying autoimmunity or hypoperfusion? Int J Endocrinol 2018:8415860PubMedPubMedCentralCrossRef González-González JG, Borjas-Almaguer OD, Salcido-Montenegro A, Rodríguez-Guajardo R, Elizondo-Plazas A, Montes-de-Oca-Luna R (2018) Sheehan’s syndrome revisited: underlying autoimmunity or hypoperfusion? Int J Endocrinol 2018:8415860PubMedPubMedCentralCrossRef
22.
go back to reference Dökmetaş HS, Kilicli F, Korkmaz S, Yonem O (2006) Characteristic features of 20 patients with Sheehan’s syndrome. Gynecol Endocrinol 22:279–283PubMedCrossRef Dökmetaş HS, Kilicli F, Korkmaz S, Yonem O (2006) Characteristic features of 20 patients with Sheehan’s syndrome. Gynecol Endocrinol 22:279–283PubMedCrossRef
23.
go back to reference Du GL, Liu ZH, Chen M, Ma R, Jiang S, Shayiti M et al (2015) Sheehan’s syndrome in xinjiang: clinical characteristics and laboratory evaluation of 97 patients. Hormones (Athens) 14:660–667PubMed Du GL, Liu ZH, Chen M, Ma R, Jiang S, Shayiti M et al (2015) Sheehan’s syndrome in xinjiang: clinical characteristics and laboratory evaluation of 97 patients. Hormones (Athens) 14:660–667PubMed
24.
go back to reference Gei-Guardia O, Soto-Herrera E, Gei-Brealey A, Chen-Ku CH (2011) Sheehan syndrome in Costa Rica: clinical experience with 60 cases. Endocr Pract 17:337–344PubMedCrossRef Gei-Guardia O, Soto-Herrera E, Gei-Brealey A, Chen-Ku CH (2011) Sheehan syndrome in Costa Rica: clinical experience with 60 cases. Endocr Pract 17:337–344PubMedCrossRef
25.
go back to reference Gokalp D, Alpagat G, Tuzcu A, Bahceci M, Tuzcu S, Yakut F et al (2016) Four decades without diagnosis: Sheehan’s syndrome, a retrospective analysis. Gynecol Endocrinol 32:904–907PubMedCrossRef Gokalp D, Alpagat G, Tuzcu A, Bahceci M, Tuzcu S, Yakut F et al (2016) Four decades without diagnosis: Sheehan’s syndrome, a retrospective analysis. Gynecol Endocrinol 32:904–907PubMedCrossRef
26.
go back to reference Kelestimur F, Jonsson P, Molvalilar S, Gomez JM, Auernhammer CJ, Colak R et al (2005) Sheehan’s syndrome: baseline characteristics and effect of 2 years of growth hormone replacement therapy in 91 patients in KIMS - Pfizer international metabolic database. Eur J Endocrinol 152:581–587PubMedCrossRef Kelestimur F, Jonsson P, Molvalilar S, Gomez JM, Auernhammer CJ, Colak R et al (2005) Sheehan’s syndrome: baseline characteristics and effect of 2 years of growth hormone replacement therapy in 91 patients in KIMS - Pfizer international metabolic database. Eur J Endocrinol 152:581–587PubMedCrossRef
27.
go back to reference Lim CH, Han JH, Jin J, Yu JE, Chung JO, Cho DH et al (2015) Electrolyte imbalance in patients with Sheehan’s syndrome. Endocrinol Metab (Seoul) 30:502–508PubMedCrossRef Lim CH, Han JH, Jin J, Yu JE, Chung JO, Cho DH et al (2015) Electrolyte imbalance in patients with Sheehan’s syndrome. Endocrinol Metab (Seoul) 30:502–508PubMedCrossRef
28.
go back to reference Ozbey N, Inanc S, Aral F, Azezli A, Orhan Y, Sencer E et al (1994) Clinical and laboratory evaluation of 40 patients with Sheehan’s syndrome. Isr J Med Sci 30:826–829PubMed Ozbey N, Inanc S, Aral F, Azezli A, Orhan Y, Sencer E et al (1994) Clinical and laboratory evaluation of 40 patients with Sheehan’s syndrome. Isr J Med Sci 30:826–829PubMed
29.
go back to reference Sert M, Tetiker T, Kirim S, Kocak M (2003) Clinical report of 28 patients with Sheehan’s syndrome. Endocr J 50:297–301PubMedCrossRef Sert M, Tetiker T, Kirim S, Kocak M (2003) Clinical report of 28 patients with Sheehan’s syndrome. Endocr J 50:297–301PubMedCrossRef
31.
go back to reference Furnica RM, Gadisseux P, Fernandez C, Dechambre S, Maiter D, Oriot P (2015) Early diagnosis of Sheehan’s syndrome. Anaesth Crit Care Pain Med 34:61–63PubMedCrossRef Furnica RM, Gadisseux P, Fernandez C, Dechambre S, Maiter D, Oriot P (2015) Early diagnosis of Sheehan’s syndrome. Anaesth Crit Care Pain Med 34:61–63PubMedCrossRef
32.
go back to reference Laway B, Misgar R, Mir S, Wani A (2016) Clinical, hormonal and radiological features of partial Sheehan’s syndrome: an Indian experience. Arch Endocrinol Metab 60:125–129PubMedCrossRef Laway B, Misgar R, Mir S, Wani A (2016) Clinical, hormonal and radiological features of partial Sheehan’s syndrome: an Indian experience. Arch Endocrinol Metab 60:125–129PubMedCrossRef
33.
go back to reference Uzun I, Karaca Z (2024) The diagnosis and prevalence of hypoprolactinemia in patients with panhypopituitarism and the effects on depression and sexual functions. Pituitary 27:277–286PubMedPubMedCentralCrossRef Uzun I, Karaca Z (2024) The diagnosis and prevalence of hypoprolactinemia in patients with panhypopituitarism and the effects on depression and sexual functions. Pituitary 27:277–286PubMedPubMedCentralCrossRef
34.
go back to reference Dash RJ, Gupta V, Suri S (1993) Sheehan’s syndrome: clinical profile, pituitary hormone responses and computed sellar tomography. Aust N Z J Med 23:26–31PubMedCrossRef Dash RJ, Gupta V, Suri S (1993) Sheehan’s syndrome: clinical profile, pituitary hormone responses and computed sellar tomography. Aust N Z J Med 23:26–31PubMedCrossRef
35.
go back to reference Kurtulmus N, Yarman S (2006) Hyponatremia as the presenting manifestation of Sheehan’s syndrome in elderly patients. Aging Clin Exp Res 18:536–539PubMedCrossRef Kurtulmus N, Yarman S (2006) Hyponatremia as the presenting manifestation of Sheehan’s syndrome in elderly patients. Aging Clin Exp Res 18:536–539PubMedCrossRef
36.
go back to reference Zargar AH, Masoodi SR, Laway BA, Shah NA, Salahuddin M, Siddiqi MA et al (1996) Clinical spectrum of Sheehan’s syndrome. Ann Saudi Med 16:338–341PubMedCrossRef Zargar AH, Masoodi SR, Laway BA, Shah NA, Salahuddin M, Siddiqi MA et al (1996) Clinical spectrum of Sheehan’s syndrome. Ann Saudi Med 16:338–341PubMedCrossRef
37.
38.
go back to reference Dimke H, Flyvbjerg A, Frische S (2007) Acute and chronic effects of growth hormone on renal regulation of electrolyte and water homeostasis. Growth Horm IGF Res 17:353–368PubMedCrossRef Dimke H, Flyvbjerg A, Frische S (2007) Acute and chronic effects of growth hormone on renal regulation of electrolyte and water homeostasis. Growth Horm IGF Res 17:353–368PubMedCrossRef
39.
go back to reference Hansen TK, Møller J, Thomsen K, Frandsen E, Dall R, Jørgensen JO et al (2001) Effects of growth hormone on renal tubular handling of sodium in healthy humans. Am J Physiol Endocrinol Metab 281:E1326-1332PubMedCrossRef Hansen TK, Møller J, Thomsen K, Frandsen E, Dall R, Jørgensen JO et al (2001) Effects of growth hormone on renal tubular handling of sodium in healthy humans. Am J Physiol Endocrinol Metab 281:E1326-1332PubMedCrossRef
40.
go back to reference Greenlee MM, Mitzelfelt JD, Duke BJ, Al-Khalili O, Bao HF, Eaton DC (2015) Prolactin stimulates sodium and chloride ion channels in A6 renal epithelial cells. Am J Physiol Renal Physiol 308:F697-705PubMedPubMedCentralCrossRef Greenlee MM, Mitzelfelt JD, Duke BJ, Al-Khalili O, Bao HF, Eaton DC (2015) Prolactin stimulates sodium and chloride ion channels in A6 renal epithelial cells. Am J Physiol Renal Physiol 308:F697-705PubMedPubMedCentralCrossRef
41.
go back to reference Stachenfeld NS, Keefe DL (2002) Estrogen effects on osmotic regulation of AVP and fluid balance. Am J Physiol Endocrinol Metab 283:E711-721PubMedCrossRef Stachenfeld NS, Keefe DL (2002) Estrogen effects on osmotic regulation of AVP and fluid balance. Am J Physiol Endocrinol Metab 283:E711-721PubMedCrossRef
42.
go back to reference Kim SM, Sultana F, Korkmaz F, Rojekar S, Pallapati A, Ryu V et al (2024) Neuroendocrinology of bone. Pituitary. 27:761PubMedCrossRef Kim SM, Sultana F, Korkmaz F, Rojekar S, Pallapati A, Ryu V et al (2024) Neuroendocrinology of bone. Pituitary. 27:761PubMedCrossRef
43.
go back to reference Pantazi H, Papapetrou PD (2000) Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism. J Clin Endocrinol Metab 85:1099–1106PubMedCrossRef Pantazi H, Papapetrou PD (2000) Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism. J Clin Endocrinol Metab 85:1099–1106PubMedCrossRef
44.
go back to reference Beshyah SA, Thomas E, Kyd P, Sharp P, Fairney A, Johnston DG (1994) The effect of growth hormone replacement therapy in hypopituitary adults on calcium and bone metabolism. Clin Endocrinol (Oxf) 40:383–391PubMedCrossRef Beshyah SA, Thomas E, Kyd P, Sharp P, Fairney A, Johnston DG (1994) The effect of growth hormone replacement therapy in hypopituitary adults on calcium and bone metabolism. Clin Endocrinol (Oxf) 40:383–391PubMedCrossRef
45.
go back to reference Weiner P, Ben-Israel J, Plavnick L (1979) Sheehan’s syndrome with diabetes insipidus. A case study. Isr J Med Sci 15:431–433PubMed Weiner P, Ben-Israel J, Plavnick L (1979) Sheehan’s syndrome with diabetes insipidus. A case study. Isr J Med Sci 15:431–433PubMed
46.
go back to reference Atmaca H, Tanriverdi F, Gokce C, Unluhizarci K, Kelestimur F (2007) Posterior pituitary function in Sheehan’s syndrome. Eur J Endocrinol 156:563–567PubMedCrossRef Atmaca H, Tanriverdi F, Gokce C, Unluhizarci K, Kelestimur F (2007) Posterior pituitary function in Sheehan’s syndrome. Eur J Endocrinol 156:563–567PubMedCrossRef
47.
go back to reference Karaca Z, Tanriverdi F, Atmaca H, Unluhizarci K, Kelestimur F (2012) Posterior pituitary functions are not altered after growth hormone replacement therapy in hypopituitarism due to Sheehan’s syndrome. Growth Horm IGF Res 22:146–149PubMedCrossRef Karaca Z, Tanriverdi F, Atmaca H, Unluhizarci K, Kelestimur F (2012) Posterior pituitary functions are not altered after growth hormone replacement therapy in hypopituitarism due to Sheehan’s syndrome. Growth Horm IGF Res 22:146–149PubMedCrossRef
48.
go back to reference Güven M, Bayram F, Güven K, Kelestimur F (2000) Evaluation of patients admitted with hypoglycaemia to a teaching hospital in Central Anatolia. Postgrad Med J 76:150–152PubMedPubMedCentralCrossRef Güven M, Bayram F, Güven K, Kelestimur F (2000) Evaluation of patients admitted with hypoglycaemia to a teaching hospital in Central Anatolia. Postgrad Med J 76:150–152PubMedPubMedCentralCrossRef
49.
go back to reference Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P (2004) Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized. Placebo-Controlled Trials J Clin Endocrinol Metab 89:2192–2199PubMedCrossRef Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P (2004) Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized. Placebo-Controlled Trials J Clin Endocrinol Metab 89:2192–2199PubMedCrossRef
50.
go back to reference Jasim S, Alahdab F, Ahmed AT, Tamhane S, Prokop LJ, Nippoldt TB et al (2017) Mortality in adults with hypopituitarism: a systematic review and meta-analysis. Endocrine 56:33–42PubMedCrossRef Jasim S, Alahdab F, Ahmed AT, Tamhane S, Prokop LJ, Nippoldt TB et al (2017) Mortality in adults with hypopituitarism: a systematic review and meta-analysis. Endocrine 56:33–42PubMedCrossRef
51.
go back to reference Pappachan JM, Raskauskiene D, Kutty VR, Clayton RN (2015) Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies. J Clin Endocrinol Metab 100:1405–1411PubMedCrossRef Pappachan JM, Raskauskiene D, Kutty VR, Clayton RN (2015) Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies. J Clin Endocrinol Metab 100:1405–1411PubMedCrossRef
52.
go back to reference Behan LA, Carmody D, Rogers B, Hannon MJ, Davenport C, Tormey W et al (2016) Low-dose hydrocortisone replacement is associated with improved arterial stiffness index and blood pressure dynamics in severely adrenocorticotrophin-deficient hypopituitary male patients. Eur J Endocrinol 174:791–799PubMedCrossRef Behan LA, Carmody D, Rogers B, Hannon MJ, Davenport C, Tormey W et al (2016) Low-dose hydrocortisone replacement is associated with improved arterial stiffness index and blood pressure dynamics in severely adrenocorticotrophin-deficient hypopituitary male patients. Eur J Endocrinol 174:791–799PubMedCrossRef
53.
go back to reference Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS et al (2001) Association between premature mortality and hypopituitarism. West Midlands prospective hypopituitary study group. Lancet 357:425–431PubMedCrossRef Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS et al (2001) Association between premature mortality and hypopituitarism. West Midlands prospective hypopituitary study group. Lancet 357:425–431PubMedCrossRef
54.
go back to reference Bhat MA, Laway BA, Shah ZA, Wani AI, Mubarik I (2015) Insulin resistance, metabolic syndrome and chronic low grade inflammation in Sheehan’s syndrome on standard replacement therapy: a case control study. Pituitary 18:312–318PubMedCrossRef Bhat MA, Laway BA, Shah ZA, Wani AI, Mubarik I (2015) Insulin resistance, metabolic syndrome and chronic low grade inflammation in Sheehan’s syndrome on standard replacement therapy: a case control study. Pituitary 18:312–318PubMedCrossRef
55.
go back to reference Tanriverdi F, Unluhizarci K, Kula M, Guven M, Bayram F, Kelestimur F (2005) Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan’s syndrome. Growth Horm IGF Res 15:231–237PubMedCrossRef Tanriverdi F, Unluhizarci K, Kula M, Guven M, Bayram F, Kelestimur F (2005) Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan’s syndrome. Growth Horm IGF Res 15:231–237PubMedCrossRef
56.
go back to reference Toogood AA, Taylor NF, Shalet SM, Monson JP (2000) Modulation of cortisol metabolism by low-dose growth hormone replacement in elderly hypopituitary patients. J Clin Endocrinol Metab 85:1727–1730PubMed Toogood AA, Taylor NF, Shalet SM, Monson JP (2000) Modulation of cortisol metabolism by low-dose growth hormone replacement in elderly hypopituitary patients. J Clin Endocrinol Metab 85:1727–1730PubMed
57.
go back to reference Mir SA, Shah T, Singh H, Shabir I, Laway BA (2018) Serum lipid and leptin concentrations in patients with Sheehan syndrome. Indian J Endocrinol Metab 22:466–468PubMedPubMedCentralCrossRef Mir SA, Shah T, Singh H, Shabir I, Laway BA (2018) Serum lipid and leptin concentrations in patients with Sheehan syndrome. Indian J Endocrinol Metab 22:466–468PubMedPubMedCentralCrossRef
58.
go back to reference Soares DV, Spina LD, Lima Oliveira Brasilde RR, Lobo PM, Salles E, Coeli CM et al (2006) Two years of growth hormone replacement therapy in a group of patients with Sheehan’s syndrome. Pituitary 9:127–135PubMedCrossRef Soares DV, Spina LD, Lima Oliveira Brasilde RR, Lobo PM, Salles E, Coeli CM et al (2006) Two years of growth hormone replacement therapy in a group of patients with Sheehan’s syndrome. Pituitary 9:127–135PubMedCrossRef
59.
go back to reference Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson A, Johannsson G (2006) The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 91:3954–3961PubMedCrossRef Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson A, Johannsson G (2006) The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 91:3954–3961PubMedCrossRef
60.
go back to reference Das L, Sahoo J, Dahiya N, Taneja S, Bhadada SK, Bhat MH et al (2022) Long-term hepatic and cardiac health in patients diagnosed with Sheehan’s syndrome. Pituitary 25:971–981PubMedCrossRef Das L, Sahoo J, Dahiya N, Taneja S, Bhadada SK, Bhat MH et al (2022) Long-term hepatic and cardiac health in patients diagnosed with Sheehan’s syndrome. Pituitary 25:971–981PubMedCrossRef
61.
go back to reference Hartiala O, Kajander S, Knuuti J, Ukkonen H, Saraste A, Rinta-Kiikka I et al (2016) Life-course risk factor levels and coronary artery calcification. The cardiovascular risk in young finns study. Int J Cardiol 225:23–29PubMedCrossRef Hartiala O, Kajander S, Knuuti J, Ukkonen H, Saraste A, Rinta-Kiikka I et al (2016) Life-course risk factor levels and coronary artery calcification. The cardiovascular risk in young finns study. Int J Cardiol 225:23–29PubMedCrossRef
62.
go back to reference Ridker PM, Koenig W, Kastelein JJ, Mach F, Lüscher TF (2018) Has the time finally come to measure hsCRP universally in primary and secondary cardiovascular prevention? Osteoporos Int 39:4109–4111 Ridker PM, Koenig W, Kastelein JJ, Mach F, Lüscher TF (2018) Has the time finally come to measure hsCRP universally in primary and secondary cardiovascular prevention? Osteoporos Int 39:4109–4111
63.
go back to reference Sesmilo G, Miller KK, Hayden D, Klibanski A (2001) Inflammatory cardiovascular risk markers in women with hypopituitarism. J Clin Endocrinol Metab 86:5774–5781PubMedCrossRef Sesmilo G, Miller KK, Hayden D, Klibanski A (2001) Inflammatory cardiovascular risk markers in women with hypopituitarism. J Clin Endocrinol Metab 86:5774–5781PubMedCrossRef
64.
go back to reference Bollerslev J, Ueland T, Jørgensen AP, Fougner KJ, Wergeland R, Schreiner T et al (2006) Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency. Eur J Endocrinol 154:537–543PubMedCrossRef Bollerslev J, Ueland T, Jørgensen AP, Fougner KJ, Wergeland R, Schreiner T et al (2006) Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency. Eur J Endocrinol 154:537–543PubMedCrossRef
65.
go back to reference Laway BA, Rasool A (2023) High prevalence of coronary artery calcification and increased risk for coronary artery disease in patients with Sheehan syndrome-a case-control study. Clin Endocrinol 98:375–382CrossRef Laway BA, Rasool A (2023) High prevalence of coronary artery calcification and increased risk for coronary artery disease in patients with Sheehan syndrome-a case-control study. Clin Endocrinol 98:375–382CrossRef
66.
go back to reference Singh H, Afroze M, Shafi N, Bhat JA, Kawa IA, Laway BA et al (2022) Prevalence of coronary calcium deposits in Sheehan’s syndrome patients on long term replacement treatment. Pituitary 25:92–99PubMedCrossRef Singh H, Afroze M, Shafi N, Bhat JA, Kawa IA, Laway BA et al (2022) Prevalence of coronary calcium deposits in Sheehan’s syndrome patients on long term replacement treatment. Pituitary 25:92–99PubMedCrossRef
67.
go back to reference Laway BA, Ramzan M, Allai MS, Wani AI, Misgar RA (2016) Cardiac structural and functional abnormalities in females with untreated hypopituitarism due to Sheehan syndrome: response to hormone replacement therapy. Endocr Pract 22:1096–1103PubMedCrossRef Laway BA, Ramzan M, Allai MS, Wani AI, Misgar RA (2016) Cardiac structural and functional abnormalities in females with untreated hypopituitarism due to Sheehan syndrome: response to hormone replacement therapy. Endocr Pract 22:1096–1103PubMedCrossRef
68.
go back to reference Tanriverdi F, Eryol NK, Atmaca H, Unluhizarci K, Ozdogru I, Sarikaya I et al (2005) The effects of 12 months of growth hormone replacement therapy on cardiac autonomic tone in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 62:706–712PubMedCrossRef Tanriverdi F, Eryol NK, Atmaca H, Unluhizarci K, Ozdogru I, Sarikaya I et al (2005) The effects of 12 months of growth hormone replacement therapy on cardiac autonomic tone in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 62:706–712PubMedCrossRef
69.
go back to reference Leong KS, Mann P, Wallymahmed M, MacFarlane IA, Wilding JP (2001) The influence of growth hormone replacement on heart rate variability in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 54:819–826PubMedCrossRef Leong KS, Mann P, Wallymahmed M, MacFarlane IA, Wilding JP (2001) The influence of growth hormone replacement on heart rate variability in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 54:819–826PubMedCrossRef
70.
go back to reference Reddy MS, Nahar A, Thippeswamy H, Kumar CS (2017) Psychosis as a late manifestation of Sheehan’s syndrome. J Bone Miner Metab 25:228–230 Reddy MS, Nahar A, Thippeswamy H, Kumar CS (2017) Psychosis as a late manifestation of Sheehan’s syndrome. J Bone Miner Metab 25:228–230
71.
go back to reference Slagboom TNA, Deijen JB, Van Bunderen CC, Knoop HA, Drent ML (2021) Impaired neuropsychological functioning in patients with hypopituitarism. Endocrinol Diabetes Metab 4:e00165PubMedCrossRef Slagboom TNA, Deijen JB, Van Bunderen CC, Knoop HA, Drent ML (2021) Impaired neuropsychological functioning in patients with hypopituitarism. Endocrinol Diabetes Metab 4:e00165PubMedCrossRef
72.
go back to reference Lu Y, Wei R, Li S, Peng L, Shi Z (2023) Inflammatory factor levels and clinical characteristics of mental disorders in patients with sheehan syndrome. Altern Ther Health Med 29:218–223PubMed Lu Y, Wei R, Li S, Peng L, Shi Z (2023) Inflammatory factor levels and clinical characteristics of mental disorders in patients with sheehan syndrome. Altern Ther Health Med 29:218–223PubMed
73.
go back to reference Slagboom TNA, Deijen JB, Van Bunderen CC, Knoop HA, Drent ML (2021) Psychological well-being and illness perceptions in patients with hypopituitarism. Pituitary 24:542–554PubMedPubMedCentralCrossRef Slagboom TNA, Deijen JB, Van Bunderen CC, Knoop HA, Drent ML (2021) Psychological well-being and illness perceptions in patients with hypopituitarism. Pituitary 24:542–554PubMedPubMedCentralCrossRef
74.
go back to reference Slawik M, Klawitter B, Meiser E, Schories M, Zwermann O, Borm K et al (2007) Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine. J Clin Endocrinol Metab 92:4115–4122PubMedCrossRef Slawik M, Klawitter B, Meiser E, Schories M, Zwermann O, Borm K et al (2007) Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine. J Clin Endocrinol Metab 92:4115–4122PubMedCrossRef
75.
go back to reference Imran SA, Wilkinson M (2024) Cognition and psychological wellbeing in hypopituitary patients. Rev Endocr Metab Disord 25:505–512PubMedCrossRef Imran SA, Wilkinson M (2024) Cognition and psychological wellbeing in hypopituitary patients. Rev Endocr Metab Disord 25:505–512PubMedCrossRef
76.
go back to reference Naicker M, Naidoo S (2022) Cellular and molecular distribution of thyroid-specific proteins, thyroid-stimulating hormone receptor (TSH-R) and thyroglobulin (TG) in the central nervous system. J Clin Endocrinol Metab 155:105305 Naicker M, Naidoo S (2022) Cellular and molecular distribution of thyroid-specific proteins, thyroid-stimulating hormone receptor (TSH-R) and thyroglobulin (TG) in the central nervous system. J Clin Endocrinol Metab 155:105305
77.
go back to reference Golgeli A, Tanriverdi F, Suer C, Gokce C, Ozesmi C, Bayram F et al (2004) Utility of P300 auditory event related potential latency in detecting cognitive dysfunction in growth hormone (GH) deficient patients with Sheehan’s syndrome and effects of GH replacement therapy. Eur J Endocrinol 150:153–159PubMedCrossRef Golgeli A, Tanriverdi F, Suer C, Gokce C, Ozesmi C, Bayram F et al (2004) Utility of P300 auditory event related potential latency in detecting cognitive dysfunction in growth hormone (GH) deficient patients with Sheehan’s syndrome and effects of GH replacement therapy. Eur J Endocrinol 150:153–159PubMedCrossRef
79.
go back to reference Ismailogullari S, Tanriverdi F, Kelestimur F, Aksu M (2009) Sleep architecture in Sheehan’s syndrome before and 6 months after growth hormone replacement therapy. Psychoneuroendocrinology 34:212–219PubMedCrossRef Ismailogullari S, Tanriverdi F, Kelestimur F, Aksu M (2009) Sleep architecture in Sheehan’s syndrome before and 6 months after growth hormone replacement therapy. Psychoneuroendocrinology 34:212–219PubMedCrossRef
80.
go back to reference Kao KT, Stargatt R, Zacharin M (2015) Adult quality of life and psychosocial outcomes of childhood onset hypopituitarism. Horm Res Paediatr 84:94–101PubMedCrossRef Kao KT, Stargatt R, Zacharin M (2015) Adult quality of life and psychosocial outcomes of childhood onset hypopituitarism. Horm Res Paediatr 84:94–101PubMedCrossRef
82.
go back to reference Acibucu F, Kilicli F, Dokmetas HS (2014) Assessment of bone mineral density in patients with Sheehan’s syndrome. Gynecol Endocrinol 30:532–535PubMedCrossRef Acibucu F, Kilicli F, Dokmetas HS (2014) Assessment of bone mineral density in patients with Sheehan’s syndrome. Gynecol Endocrinol 30:532–535PubMedCrossRef
83.
go back to reference Chihaoui M, Yazidi M, Chaker F, Belouidhnine M, Kanoun F, Lamine F et al (2016) Bone mineral density in Sheehan’s syndrome; prevalence of low bone mass and associated factors. J Clin Densitom 19:413–418PubMedCrossRef Chihaoui M, Yazidi M, Chaker F, Belouidhnine M, Kanoun F, Lamine F et al (2016) Bone mineral density in Sheehan’s syndrome; prevalence of low bone mass and associated factors. J Clin Densitom 19:413–418PubMedCrossRef
84.
go back to reference Agarwal P, Gomez R, Bhatia E, Yadav S (2019) Decreased bone mineral density in women with Sheehan’s syndrome and improvement following oestrogen replacement and nutritional supplementation. J Bone Miner Metab 37:171–178PubMedCrossRef Agarwal P, Gomez R, Bhatia E, Yadav S (2019) Decreased bone mineral density in women with Sheehan’s syndrome and improvement following oestrogen replacement and nutritional supplementation. J Bone Miner Metab 37:171–178PubMedCrossRef
85.
go back to reference Mandal S, Mukhopadhyay P, Banerjee M, Ghosh S (2020) Clinical, endocrine, metabolic profile, and bone health in Sheehan’s syndrome. Indian J Endocrinol Metab 24:338–342PubMedPubMedCentralCrossRef Mandal S, Mukhopadhyay P, Banerjee M, Ghosh S (2020) Clinical, endocrine, metabolic profile, and bone health in Sheehan’s syndrome. Indian J Endocrinol Metab 24:338–342PubMedPubMedCentralCrossRef
86.
go back to reference de Sá CD, da Silva Castro MG, Quidute ARP, Martins MRA, Cid A, de Barros Silva PG et al (2019) Evaluation of bone texture imaging parameters on panoramic radiographs of patients with Sheehan’s syndrome: a STROBE-compliant case-control study. Osteoporos Int 30:2257–2269PubMedCrossRef de Sá CD, da Silva Castro MG, Quidute ARP, Martins MRA, Cid A, de Barros Silva PG et al (2019) Evaluation of bone texture imaging parameters on panoramic radiographs of patients with Sheehan’s syndrome: a STROBE-compliant case-control study. Osteoporos Int 30:2257–2269PubMedCrossRef
87.
go back to reference Das L, Laway BA, Sahoo J, Dhiman V, Singh P, Rao SD (2024) Bone mineral density, turnover, and microarchitecture assessed by second-generation high-resolution peripheral quantitative computed tomography in patients with Sheehan’s syndrome. Osteoporos Int 35:919–927PubMedCrossRef Das L, Laway BA, Sahoo J, Dhiman V, Singh P, Rao SD (2024) Bone mineral density, turnover, and microarchitecture assessed by second-generation high-resolution peripheral quantitative computed tomography in patients with Sheehan’s syndrome. Osteoporos Int 35:919–927PubMedCrossRef
88.
go back to reference Tritos NA, Hamrahian AH, King D, Greenspan SL, Cook DM, Jönsson PJ et al (2013) Predictors of the effects of 4 years of growth hormone replacement on bone mineral density in patients with adult-onset growth hormone deficiency - a KIMS database analysis. Clin Endocrinol (Oxf) 79:178–184PubMedCrossRef Tritos NA, Hamrahian AH, King D, Greenspan SL, Cook DM, Jönsson PJ et al (2013) Predictors of the effects of 4 years of growth hormone replacement on bone mineral density in patients with adult-onset growth hormone deficiency - a KIMS database analysis. Clin Endocrinol (Oxf) 79:178–184PubMedCrossRef
89.
go back to reference Gao H, Xiang Q, Li J, Yu M, Lan Y, Ba J, Liu Y, Tian H (2022) Clinical analysis of the serum muscle enzyme spectrum of patients with newly diagnosed Sheehan’s syndrome. Pituitary 101:e30834 Gao H, Xiang Q, Li J, Yu M, Lan Y, Ba J, Liu Y, Tian H (2022) Clinical analysis of the serum muscle enzyme spectrum of patients with newly diagnosed Sheehan’s syndrome. Pituitary 101:e30834
90.
go back to reference Bhat MA, Laway BA, Allaqaband FA, Kotwal SK, Wani IA, Banday KA (2012) Acute renal failure: a rare presentation of Sheehan’s syndrome. Indian J Endocrinol Metab 16:306–309PubMedPubMedCentralCrossRef Bhat MA, Laway BA, Allaqaband FA, Kotwal SK, Wani IA, Banday KA (2012) Acute renal failure: a rare presentation of Sheehan’s syndrome. Indian J Endocrinol Metab 16:306–309PubMedPubMedCentralCrossRef
91.
go back to reference Esposito D, Tivesten Å, Olivius C, Ragnarsson O, Johannsson G (2024) Androgen deficiency in hypopituitary women: its consequences and management. Rev Endocr Metab Disord 25:479–488PubMedPubMedCentralCrossRef Esposito D, Tivesten Å, Olivius C, Ragnarsson O, Johannsson G (2024) Androgen deficiency in hypopituitary women: its consequences and management. Rev Endocr Metab Disord 25:479–488PubMedPubMedCentralCrossRef
92.
go back to reference Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R et al (2016) Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101:3888–3921PubMedCrossRef Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R et al (2016) Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101:3888–3921PubMedCrossRef
93.
go back to reference Nilsson AG, Marelli C, Fitts D, Bergthorsdottir R, Burman P, Dahlqvist P et al (2014) Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency. Eur J Endocrinol 171:369–377PubMedPubMedCentralCrossRef Nilsson AG, Marelli C, Fitts D, Bergthorsdottir R, Burman P, Dahlqvist P et al (2014) Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency. Eur J Endocrinol 171:369–377PubMedPubMedCentralCrossRef
94.
go back to reference Oksnes M, Björnsdottir S, Isaksson M, Methlie P, Carlsen S, Nilsen RM et al (2014) Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of addison’s disease: a randomized clinical trial. J Clin Endocrinol Metab 99:1665–1674PubMedCrossRef Oksnes M, Björnsdottir S, Isaksson M, Methlie P, Carlsen S, Nilsen RM et al (2014) Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of addison’s disease: a randomized clinical trial. J Clin Endocrinol Metab 99:1665–1674PubMedCrossRef
95.
go back to reference Giavoli C, Libé R, Corbetta S, Ferrante E, Lania A, Arosio M et al (2004) Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients. J Clin Endocrinol Metab 89:5397–5401PubMedCrossRef Giavoli C, Libé R, Corbetta S, Ferrante E, Lania A, Arosio M et al (2004) Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients. J Clin Endocrinol Metab 89:5397–5401PubMedCrossRef
97.
go back to reference Leung KC, Johannsson G, Leong GM, Ho KK (2004) Estrogen regulation of growth hormone action. Endocr Rev 25:693–721PubMedCrossRef Leung KC, Johannsson G, Leong GM, Ho KK (2004) Estrogen regulation of growth hormone action. Endocr Rev 25:693–721PubMedCrossRef
98.
go back to reference Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML (2011) Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1587–1609PubMedCrossRef Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML (2011) Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1587–1609PubMedCrossRef
99.
go back to reference Mandal S, Mukhopadhyay P, Ghosh S (2022) DHEA on sexual function in sheehan syndrome: a randomized double-blind placebo-controlled crossover trial. J Clin Endocrinol Metab 107:e3395–e3402PubMedCrossRef Mandal S, Mukhopadhyay P, Ghosh S (2022) DHEA on sexual function in sheehan syndrome: a randomized double-blind placebo-controlled crossover trial. J Clin Endocrinol Metab 107:e3395–e3402PubMedCrossRef
Metadata
Title
Sheehan syndrome: a current approach to a dormant disease
Authors
Zuleyha Karaca
Fahrettin Kelestimur
Publication date
01-02-2025
Publisher
Springer US
Published in
Pituitary / Issue 1/2025
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-024-01481-1

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more